Khiyam Hussain, Rena Liu, Rosanna C G Smith, Kri T J Müller, Mohammadmersad Ghorbani, Sofia Macari, Kirstie L S Cleary, Robert J Oldham, Russell B Foxall, Sonya James, Steven G Booth, Tom Murray, Lekh N Dahal, Chantal E Hargreaves, Robert S Kemp, Jemma Longley, James Douglas, Hannah Markham, Serena J Chee, Richard J Stopforth, Ali Roghanian, Matthew J Carter, Christian H Ottensmeier, Bjorn Frendéus, Ramsey I Cutress, Ruth R French, Martin J Glennie, Jonathan C Strefford, Stephen M Thirdborough, Stephen A Beers, Mark S Cragg
BACKGROUND: Hypoxia is a hallmark of the tumor microenvironment (TME) and in addition to altering metabolism in cancer cells, it transforms tumor-associated stromal cells. Within the tumor stromal cell compartment, tumor-associated macrophages (TAMs) provide potent pro-tumoral support. However, TAMs can also be harnessed to destroy tumor cells by monoclonal antibody (mAb) immunotherapy, through antibody dependent cellular phagocytosis (ADCP). This is mediated via antibody-binding activating Fc gamma receptors (FcγR) and impaired by the single inhibitory FcγR, FcγRIIb...
April 7, 2022: Journal of Experimental & Clinical Cancer Research: CR